PROGRAM CHAIR
Rishi P. Singh, MD, FASRS
Vice President/Chief Medical Officer of Martin North and South Hospitals
Professor of Ophthalmology, Cleveland Clinic Lerner College of Medicine
Cleveland Clinic Martin Health
Stuart, FL
FACULTY
Jason Hsu, MD
Co-Director of Retina Research
The Retina Service of Wills Eye Hospital
Professor of Clinical Ophthalmology
Thomas Jefferson University
Philadelphia, PA
PROGRAM OVERVIEW
This program will offer ophthalmologists and retina specialties the opportunity to integrate research about barriers to care that contribute to poorer vision outcomes in treatment of neovascular age-related macular degeneration (nAMD). This activity will have didactic presentation and case-based discussions to acquire knowledge and tactics to address these barriers and optimize outcomes through individualized approaches to treatment, including dosing strategies and the use of next-generation anti-VEGF therapy. An animated whiteboard enhances comprehension of the mechanisms of anti-VEGF therapy and demonstrates how expanded dosing intervals available through next-generation anti-VEGF therapy can help reduce the burden of care.
TARGET AUDIENCE
This initiative is designed to meet the educational needs of retina specialists, comprehensive ophthalmologists, and retina fellows involved in the management of patients with retinal vascular disease.
LEARNING OBJECTIVES
- Evaluate adherence barriers in nAMD treatment, including injection frequency and patient factors
- Analyze the duration of effectiveness in established and emerging therapies for nAMD
- Identify patients eligible for dosing modifications or transitioning to longer-lasting therapies, based on individual, treatment, and disease considerations
- Personalize treatment selection and dosing strategies to optimize care for nAMD patients
JOINT ACCREDITATION STATEMENT
In support of improving patient care, Med Learning Group is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
PHYSICIAN CREDIT DESIGNATION STATEMENT
Med Learning Group designates this enduring activity for a maximum of 1.0 AMA PRA Category 1 CreditTM. Physicians should claim only the credit commensurate with the extent of their participation in the enduring activity.
NURSES (ANCC) CREDIT DESIGNATION
Med Learning Group designates this activity for a maximum of 1.0 ANCC contact hour.
DISCLOSURE POLICY STATEMENT
In accordance with the Accreditation Council for Continuing Medical Education ACCME Standards for Integrity and Independence in Accredited Continuing Education, educational programs sponsored by Med Learning Group must demonstrate balance, independence, objectivity, and scientific rigor. All faculty, authors, editors, staff, and planning committee members participating in an MLG‐sponsored activity are required to disclose any relevant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services that are discussed in an educational activity.
DISCLOSURE OF RELEVANT FINANCIAL RELATIONSHIPS
| Faculty Member | Disclosures |
| Rishi P. Singh, MD | Disclosures receiving consulting fees from Apellis Pharmaceuticals, Iveric Bio, Eyepoint Pharmaceuticals, RegenxBio, Genentech, Bausch + Lomb, Zeiss, Alcon, and Regeneron Pharmaceuticals, Inc. Additionally, discloses contracted research for Janssen Pharmaceuticals. |
| Jason Hsu, MD | Discloses receiving consulting fees from Astellas/Iveric Bio, and Gyroscope Therapeutics. Additionally, discloses contracted research for Astellas, Iveric Bio, Genentech/Roche, Stealth BioTherapeutics, and Regeneron Pharmaceuticals, Inc. |
All relevant financial relationships have been mitigated.
Content Review
The content of this activity was independently peer reviewed by a physician and nurse reviewer.
Individuals in Control of the Content of the Activity
The individuals in control of the content of this activity have reported the following financial relationships or relationships to products or devices they have with ineligible companies related to the content of this CE activity:
- Matthew Frese, General Manager of Med Learning Group, has nothing to disclose.
- Christina Gallo, SVP, Educational Development of Med Learning Group, has nothing to disclose.
- Sharon Windsor Harker, Medical Director of Med Learning Group, has nothing to disclose.
- Nicole Longo, DO, FACOI, VP of Med/Sci Services and Learner Engagement of Med Learning Group, has nothing to disclose.
- Ana Maria Albino, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Lauren Bartunek, Senior Program Manager of Med Learning Group, has nothing to disclose.
- Heather Gee, Program Coordinator of Med Learning Group, has nothing to disclose.
- Lauren Welch, MA, VP of Accreditation and Outcomes of Med Learning Group, has nothing to disclose.
- Daniel DaSilva, Accreditation and Outcomes Coordinator of Med Learning Group, has nothing to disclose.
- Brianna Hefele, PA-C, has nothing to disclose.
- A medical reviewer from CME Peer Review LLC has nothing to disclose.
DISCLOSURE OF UNLABELED USE
Med Learning Group requires that faculty participating in any CE activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States. During the course of this lecture, the faculty may mention the use of medications for both FDA‐approved and non‐approved indications.
METHOD OF PARTICIPATION
There are no fees for participating and receiving CE credit for this activity. In order to obtain your certificate for the mentioned accreditation, participants need to successfully complete the associated pre/post activities and evaluation. Your certificate will be provided as a downloadable file.
DISCLAIMER
Med Learning Group makes every effort to develop CE activities that are scientifically based. This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development in an effort to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision‐making expertise before applying any information, whether provided here or by others, for any professional use.
For CE questions, please contact Med Learning Group at [email protected]
Contact this CE provider at Med Learning Group for privacy and confidentiality policy statement information at www.medlearninggroup.com/privacy-policy/
AMERICANS WITH DISABILITIES ACT
Event staff will be glad to assist you with any special needs. Please contact Med Learning Group prior to participating at [email protected]
RELEASED DATE: December 20, 2024
EXPIRATION DATE: December 20, 2025
Copyright © 2024 Med Learning Group. All rights reserved. These materials may be used for personal use only. Any rebroadcast, distribution, or reuse of this presentation or any part of it in any form for other than personal use without the express written permission of Med Learning Group is prohibited.
